Press Releases

Filter Press Releases:



  • Lilly Reports First-Quarter 2017 Results

    INDIANAPOLIS, April 25, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced financial results for the first quarter of 2017.   $ in millions, except per share data First Quarter % 2017 2016 Change Revenue $ 5,228.3 $ 4,865.1 7 % Net Income (Loss) - Reported (110.8)…

  • Lilly Announces Phase 3 MONARCH 3 Breast Cancer Study of Abemaciclib Demonstrated Superior Progression-Free Survival at Interim Analysis

    INDIANAPOLIS, April 24, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that following a pre-planned interim analysis for MONARCH 3, the trial met its primary endpoint of demonstrating statistically significant improvement in progression-free survival (PFS). In addition, improvement was shown in a key secondary endpoint of objective response rate (ORR). The Phase 3 study ev…

  • Lilly to Present Data for Galcanezumab for the Prevention of Migraine at the American Academy of Neurology (AAN) Annual Meeting

    INDIANAPOLIS, April 20, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will highlight Phase 2 data evaluating galcanezumab for the prevention of migraine at the American Academy of Neurology (AAN) annual meeting, which will take place April 22-28, 2017, in Boston. Lilly will present four abstracts at AAN, including safety and patient outcomes data for galcanezumab in patients with mig…

  • U.S. FDA Issues Complete Response Letter for Baricitinib

    INDIANAPOLIS--(BUSINESS WIRE)-- Eli Lilly and Company (NYSE:LLY) and Incyte Corporation (NASDAQ:INCY) announced today that the U.S. Food and Drug Administration (FDA) has issued a complete response letter for the New Drug Application (NDA) of the investigational medicine baricitinib, a once-daily oral medication for the treatment of moderate-to-severe rheumatoid…

  • Lilly Confirms Date and Conference Call for First-Quarter 2017 Financial Results Announcement

    INDIANAPOLIS, April 11, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will announce its financial results for the first quarter of 2017 on Tuesday, April 25, 2017. Lilly will also conduct a conference call on that day with the investment community and media to further detail the company's financial performance. The conference call will begin at 9 a.m. Eastern time. Investors, media an…

  • Life with Type 1 Diabetes Made a Little Easier through Lilly Diabetes Scholarship Donations for Camps, College and Conferences

    INDIANAPOLIS, ARLINGTON, Va. and ROLLING MEADOWS, Ill., April 7, 2017 /PRNewswire/ -- Living with type 1 diabetes comes with many unique challenges in all stages of life. For parents of children with the condition, financial, medical and emotional worries can be overwhelming. To help support people with diabetes and those who love them, Lilly Diabetes today announced it will donate $94,000 to the…

  • Lilly and Ohio University Heritage College of Osteopathic Medicine Partner on Rotation Program for Medical Students

    INDIANAPOLIS, April 4, 2017 /PRNewswire/ -- Students from Ohio University's Heritage College of Osteopathic Medicine will soon join Eli Lilly and Company's (NYSE: LLY) innovative rotation program for aspiring physicians. Launched in early 2014, the program provides students with hands-on experience in a range of pharmaceutical business activities, from drug discovery and development to bioethics…

  • Lilly Announces $850 Million Investment in U.S. Capital Projects in 2017

    INDIANAPOLIS, March 24, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced plans to invest $850 million in its U.S. operations in 2017. The company's investments span facilities across its U.S. enterprise, including research laboratories, manufacturing sites, and general and administrative areas. The investments are being driven by demand for Lilly products, as well as its rob…

  • Lilly and the William Sansum Diabetes Center announce a five-year research collaboration

    SANTA BARBARA, Calif. and INDIANAPOLIS, March 23, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and the William Sansum Diabetes Center have established a research collaboration to improve the lives of Latino people affected by diabetes through enhanced research, education and care. "The tremendous burden of diabetes and cardiovascular disease bears a disproportionate weight on Latino…

  • Lilly Announces Phase 3 MONARCH 2 Breast Cancer Study of Abemaciclib Met Primary Endpoint of Progression-Free Survival

    INDIANAPOLIS, March 20, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that its MONARCH 2 trial of abemaciclib met the primary endpoint of progression-free survival (PFS). The Phase 3 study evaluated abemaciclib, a cyclin-dependent kinase (CDK) 4 and CDK 6 inhibitor, in combination with fulvestrant in women with hormone-receptor-positive (HR+), human epidermal growth facto…

  • First dedicated outcome trials of empagliflozin in chronic heart failure initiated

    RIDGEFIELD, Conn. and INDIANAPOLIS, March 17, 2017 /PRNewswire/ -- Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) today announced that the EMPEROR HF clinical trial program was initiated. EMPEROR HF comprises two phase III outcome studies that will investigate empagliflozin for the treatment of adults with chronic heart failure. The trials will involve not only adults with type 2 diab…

  • New Head-to-Head Data Shows Significantly Higher Response Rates for Lilly's Taltz® (ixekizumab) Compared to Stelara® (ustekinumab) in Patients with Moderate-to-Severe Plaque Psoriasis

    Lilly to present head-to-head 24-week data comparing the efficacy and safety of Taltz and Stelara for the treatment of moderate-to-severe plaque psoriasis INDIANAPOLIS, March 4, 2017 /CNW/ -- Eli Lilly and Company (NYSE: LLY) announced today that patients with moderate-to-severe plaque psoriasis treated with Taltz® (ixekizumab) demonstrated superior efficacy at 24 weeks compared to pa…

  • Lilly Diabetes Becomes 'Official Diabetes Health Partner of NASCAR®'

    DAYTONA BEACH, Fla., March 3, 2017 /PRNewswire/ -- NASCAR® and Lilly Diabetes announced today that Lilly is expanding its involvement in NASCAR with a multi-year official partnership with the sanctioning body. The new collaboration designates Lilly Diabetes as the "Official Diabetes Health Partner of NASCAR." The partnership with Lilly Diabetes builds upon its primary sponsorship of the…

  • Lilly Announces Changes in Senior Management

    INDIANAPOLIS, March 2, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced changes in its executive committee. Johna Norton will be promoted to senior vice president of global quality April 1, replacing Fionnuala Walsh, who is retiring April 15 after 28 years at Lilly. Norton currently is vice president, Global Quality for API Manufacturing, Product Research and Developme…

  • Lilly Completes Acquisition of CoLucid Pharmaceuticals

    INDIANAPOLIS, March 1, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) today announced the successful completion of its acquisition of CoLucid Pharmaceuticals, Inc. (NASD:CLCD). The tender offer for all outstanding shares of common stock of CoLucid, at a price of $46.50 per share, expired as scheduled on Tuesday, February 28, 2017. As of the expiration of the tender offer, 17,410,607 sh…

  • Lilly to Present New Data for Taltz® (ixekizumab) in Psoriasis and Psoriatic Arthritis at the American Academy of Dermatology (AAD) Annual Meeting

    INDIANAPOLIS, Feb. 28, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will highlight new Phase 3 data evaluating Taltz® (ixekizumab) for the treatment of moderate-to-severe plaque psoriasis and active psoriatic arthritis at the 75th annual meeting of the American Academy of Dermatology (AAD), which will take place March 3-7, 2017, in Orlando, Fla. Lilly will present 14 abstracts,…

  • Lilly To Present At Leerink Partners Global Healthcare Conference

    INDIANAPOLIS, Feb. 9, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will present at the Leerink Partners Global Healthcare Conference on Thursday, February 16, 2017. Enrique Conterno, senior vice president of Lilly and president of Lilly Diabetes and Lilly USA, will participate in a fireside chat at 1:30 p.m., Eastern Time. A live audio webcast will be available on the "Webcasts & Pr…

  • Carolyn R. Bertozzi, Ph.D., Elected to Lilly Board of Directors

    INDIANAPOLIS, Feb. 9, 2017 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY) has elected Carolyn R. Bertozzi, Ph.D., as a new member, effective Feb. 10, 2017. As a member of Lilly's board, she will serve on the Science and Technology and Public Policy and Compliance Committees of the board. Professor Bertozzi is the Anne T. and Robert M. Bass Professor of Chemistry an…

  • Lilly to Present at Cowen Health Care Conference

    INDIANAPOLIS, Feb. 8, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will present at the Cowen and Company 37th Annual Health Care Conference on Tuesday, March 7, 2017. David A. Ricks, Lilly's president and chief executive officer, will speak at 8:40 a.m., Eastern Time. A live audio webcast will be available on the "Webcasts & Presentations" section of Lilly's Investor website at http…

  • Japan IP High Court Rules In Lilly's Favor On Alimta Vitamin Regimen Patents

    INDIANAPOLIS, Feb. 2, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that the Japan IP High Court confirmed the decisions of the Japan Patent Office and ruled in Lilly's favor in the invalidation trials initiated by Sawai regarding Lilly's vitamin regimen patents for Alimta. In the fourth quarter of 2015, the Japan Patent Office issued written decisions upholding the v…

  • Lilly Reports Fourth-Quarter and Full-Year 2016 Results

    INDIANAPOLIS, Jan. 31, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced financial results for the fourth quarter and full year of 2016.   $ in millions, except per share data Fourth Quarter % Full Year % 2016 2015 Change 2016 2015 Change Revenue $ 5,760.5…

  • Lilly Revises Time for Conference Call for Fourth-Quarter 2016 Financial Results Announcement

    INDIANAPOLIS, Jan. 30, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will host a call for investors, media and the general public at 11:30 a.m. Eastern Time on January 31, 2017 to discuss the company's fourth-quarter and full-year 2016 financial results. Originally, the call had been scheduled to begin at 9:00 a.m. Eastern Time. A live webcast of the conference call will be available thr…

  • Lilly and CoLucid Pharmaceuticals Announce Agreement for Lilly To Acquire CoLucid

    INDIANAPOLIS and CAMBRIDGE, Mass., Jan. 18, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and CoLucid Pharmaceuticals, Inc. (NASD: CLCD) today announced an agreement for Lilly to acquire CoLucid for $46.50 per share or approximately $960 million. This all-cash transaction will enhance Lilly's existing portfolio in pain management for migraine, while adding a potential near-term launch to…

  • U.S. Court of Appeals Rules In Lilly's Favor On Alimta Vitamin Regimen Patent

    INDIANAPOLIS, Jan. 12, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Court of Appeals for the Federal Circuit has upheld the district court's decision and ruled in the company's favor regarding validity and infringement of the vitamin regimen patent for Alimta® (pemetrexed for injection). In the case of Eli Lilly and Company v. Teva Parenteral Medici…

  • Lilly Confirms Date and Conference Call for Fourth-Quarter 2016 Financial Results Announcement

    INDIANAPOLIS, Jan. 5, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will announce its fourth-quarter and full-year 2016 financial results on Tuesday, January 31, 2017. Lilly will also conduct a conference call on that day with the investment community and media to further detail the company's financial performance. The conference call will begin at 9 a.m. Eastern time. Investors, medi…

  • Lilly to Adjust Organization and Leadership Structure to Better Align with Growth Opportunities

    INDIANAPOLIS, Jan. 5, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced a series of changes to its organization and leadership structure to better align them with the company's growth opportunities. Explaining the need for these changes, David A. Ricks, Lilly's president and CEO, said, "Lilly begins 2017 with a clear view of its opportunities for growth in the years ahead.…

  • Elanco Animal Health Completes Acquisition of Boehringer Ingelheim Vetmedica's U.S. Feline, Canine and Rabies Vaccines Portfolio

    GREENFIELD, Ind., Jan. 3, 2017 /PRNewswire/ -- Today Elanco US Inc., a subsidiary of Eli Lilly and Company (NYSE: LLY), announced that it has completed the acquisition of Boehringer Ingelheim Vetmedica, Inc's (BIVI) U.S. feline, canine and rabies vaccines portfolio - as well as a fully integrated manufacturing and R&D site and several pipeline assets. The acq…

  • Lilly to Present at J.P. Morgan Healthcare Conference

    INDIANAPOLIS, Jan. 3, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will present at the 35th Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2017. David A. Ricks, Lilly's president and chief executive officer, will make a formal presentation from 7:30 p.m. to 7:55 p.m. Eastern time. A live audio webcast will be available on the "Webcasts & Presentations" section of L…

  • Lilly Provides 2017 Financial Guidance and 2016 Update, Reaffirms Financial Expectations Through the Remainder of the Decade

    INDIANAPOLIS, Dec. 15, 2016 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced its 2017 financial guidance and highlighted key events for the upcoming year. The company reaffirmed its financial expectations through the remainder of the decade, including at least 5 percent average annual revenue growth driven by volume and an increase in gross margin as a percent of revenue, both on…

  • Lilly Announces Dividend Increase

    INDIANAPOLIS, Dec. 12, 2016 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY) today announced a 2 percent increase in its quarterly dividend. The dividend for the first quarter of 2017 will be $0.52 per share on outstanding common stock. This raises the annual indicated rate to $2.08 per share.  The dividend is payable March 10, 2017, to shareholders of record at of…

  • Eli Lilly and Company Sponsors Arthritis Foundation 'Living Your Yes With RA,' an Initiative to Provide Resources for the Rheumatoid Arthritis Community

    INDIANAPOLIS, Oct. 12, 2016 /PRNewswire/ -- Supported by Eli Lilly and Company (NYSE: LLY), the Arthritis Foundation is launching 'Living Your Yes With RA,' a new initiative designed to empower people living with rheumatoid arthritis (RA) by giving them tools, education and resources, allowing them to expect more from their RA treatment - seeking remission or low disease activity as the only acce…

  • Lilly's First Volunteer Teams of 2016 Depart in May for Thailand and Ghana

    INDIANAPOLIS, May 19, 2016 /PRNewswire/ -- A team of Eli Lilly and Company (NYSE: LLY) volunteers from its operations worldwide is on the ground in Thailand, working with a local hospital and health volunteers as part of Lilly's Connecting Hearts Abroad global employee volunteer program. A second team of volunteers will depart next week to serve in Ghana. Nine more teams of Lilly volunteers will…

  • Lilly and United Way Celebrate Deepening Partnership, Community Impact

    INDIANAPOLIS, Nov. 5, 2015 /PRNewswire/ -- Representatives from Eli Lilly and Company (NYSE: LLY) and United Way and its partner agencies gathered today to celebrate the early success of a new partnership approach that includes pairing Lilly teams with United Way agencies and a record gift of $13 million. The results will be shared today from 4-6 p.m. at an Impact Celebration event hosted at the…

  • Diabetes Scholars Foundation Announces 2015 Scholarship Recipients

    ROLLING MEADOWS, Ill. and INDIANAPOLIS, June 25, 2015 /PRNewswire/ -- Attending college is a critical milestone in the lives of many young people. But balancing college life and a full course load while keeping a chronic disease such as diabetes in check can make an exciting time much more challenging. Today, the Diabetes Scholars Foundation (Foundation) announced its 2015 college scholarship rec…

  • Olympian Kris Freeman and NASCAR Driver Ryan Reed to Share Their Courageous Stories with Children Who Have Type 1 Diabetes

    INDIANAPOLIS, June 8, 2015 /PRNewswire/ -- Olympic cross-country skier Kris Freeman and NASCAR XFINITY Series driver Ryan Reed will travel across the U.S. this summer to share their stories of perseverance and triumph as part of the Lilly Camp Care Package (LCCP) program. Kris and Ryan will speak to children at select diabetes summer camps about how type 1 diabetes did not stop them from chasing…

  • Lilly commits 780,000 additional vials of insulin to Life for a Child

    INDIANAPOLIS, June 4, 2015 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) has committed another 780,000 vials of insulin to the International Diabetes Federation's Life for a Child program. Life for a Child provides free, life-saving medicine to children living in impoverished communities who otherwise would not have access to the insulin they need. The International Diabetes Federation (IDF) i…

  • Lilly Sends Employees to Serve in Vulnerable Communities around the World

    INDIANAPOLIS, May 27, 2015 /PRNewswire/ -- Marcio Donatelli, a senior marketing associate with the animal health division of Eli Lilly and Company (NYSE: LLY), believes his volunteer work in a healthcare setting in Bangkok, Thailand, will be among the most humbling experiences of his life. "Caring for people in need with respect and dignity is the guiding star for me and my fellow volunteers," sh…

  • Lilly Releases Corporate Responsibility, Global Health Reports

    INDIANAPOLIS, May 4, 2015 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today released two new reports that provide a comprehensive overview of the company's corporate responsibility efforts. The reports highlight how Lilly is evolving its approach to corporate responsibility by increasingly leveraging its assets and capabilities in partnership with others to have greater, more sustainable im…

  • Lilly, Bristol-Myers Squibb Restructure Erbitux® (cetuximab) Collaboration in North America

    Full Commercialization Rights Transferred to Lilly INDIANAPOLIS & NEW YORK--(BUSINESS WIRE)-- Eli Lilly and Company (NYSE:LLY) and Bristol-Myers Squibb Company (NYSE:BMY) today announced that the companies have agreed to transfer rights to Erbitux® (cetuximab) in North America, including the U.S., Canada, and Puerto Rico, from Br…

  • The Lilly Foundation Commits $1 Million to Support AMPATH Oncology Institute in Kenya

    INDIANAPOLIS, Feb. 4, 2015 /PRNewswire/ -- In conjunction with World Cancer Day, Eli Lilly and Company (NYSE: LLY) announced a commitment of $1 million to AMPATH in Eldoret, Kenya. The funding, provided by the Lilly Foundation, will help equip a new oncology center, hire additional staff and train local healthcare professionals—ultimately allowing AMPATH to screen, treat and provide palliat…